CREATES could face uphill battle in Senate

The Senate Judiciary Committee approved legislation on Thursday to limit the ability of branded pharmaceutical companies to block generic companies from accessing drug samples through REMS. But the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act could face an uphill battle to get a full Senate vote as the legislation is opposed by several high profile members of the chamber.

If passed, the legislation would allow generic companies to file a civil complaint against branded companies abusing REMS to block potential competitors...